Clinical characteristics and treatment data of the study population (n = 48)
| Acute lymphoblastic leukaemia (n = 22) | Other malignancy (n = 26) | Boys (n = 23) | Girls (n = 25) | |
|---|---|---|---|---|
| Age at diagnosis (years) | 7.1 (1.5 to 14.8) | 10.0 (3.4 to 16.9) | 9.5 (1.5 to 16.9) | 7.3 (1.8 to 14.5) |
| Age at study (years) | 9.3 (3.6 to 16.9) | 11.2 (4.4 to 17.7) | 11.1 (3.6 to 17.8) | 9.3 (3.8 to 16.2) |
| Bone age (years) | 9.3 (4.0 to 18.2) | 8.0 (3.5 to 18.2) | 10.0 (4.4 to 18.2) | 8.6 (3.5 to 16.0) |
| Body mass index (kg/m2) | 18.3 (13.9 to 27.3) | 17.2 (12.6 to 27.5) | 19.1 (13.2 to 27.3) | 17.4 (12.6 to 27.5) |
| Relative height (SDS) | 0.2 (−1.2 to 3.4) | −0.4 (−3.0 to 3.2) | −0.2 (−2.4 to 3.2) | 0.2 (−3.0 to 3.4) |
| Duration of treatment (years) | 2.0 (1.8 to 2.5) | 0.6 (0.3 to 2.0)‡ | 1.3 (0.3 to 2.5) | 1.3 (0.3 to 2.5) |
| Days of hospitalisation | 139.5 (89.0 to 210.0) | 93.0 (20.0 to 206.0)* | 119.0 (20.0 to 195.0) | 119.0 (21.0 to 210.0) |
| Weeks on corticosteroids | 11.0 (9.0 to 12.0) | 7.0 (2.0 to 18.0)‡ | 6.3 (2.0 to 12.0) | 7.5 (4.0 to 18.0) |
| Doses | ||||
| Corticosteroids | 5.4 (3.8 to 9.0) (n = 22) | 2.4 (0.2 to 5.0)‡(n = 11) | 5.3 (0.6 to 5.4) (n = 15) | 4.0 (0.2 to 9.0) (n = 18) |
| Cyclophosphamide | 3.0 (3.0 to 30.0) (n = 17) | 4.0 (0.04 to 82.0) (n = 15) | 3.0 (0.1 to 30.0) (n = 16) | 3.6 (0.04 to 82.0) (n = 16) |
| Cytarabine | 1.8 (0.08 to 396.0) (n = 18) | 1.8 (0.6 to 62.1)† (n = 10) | 1.8 (1.0 to 40.3) (n = 13) | 1.8 (0.08 to 396.0) (n = 15) |
| Doxorubicin | 0.1 (0.1 to 0.3) (n = 22) | 0.2 (0.08 to 0.4)* (n = 23) | 0.2 (0.08 to 0.4) (n = 23) | 0.2 (0.1 to 0.3) (n = 22) |
| Methotrexate | 45.0 (6.0 to 45.0) (n = 22) | 20.0 (3.0 to 108.0)‡ (n = 11) | 45.0 (3.0 to 108.0) (n = 16) | 40.0 (3.0 to 48.0) (n = 17) |
| Vincristine | 28.0 (20.0 to 33.0) (n = 22) | 14.8 (1.4 to 48.0)† (n = 14) | 24.0 (1.4 to 46.0) (n = 17) | 28.0 (8.4 to 48.0) (n = 19) |
Values are median (range).
Chemotherapeutic agents as intravenous cumulative doses (g/m2; vincristine, mg/m2); corticosteroids as oral equivalent doses of prednisolone (g/m2).*p ⩽ 0.01; †p < 0.001; ‡p < 0.0001; all compared with acute lymphoblastic leukaemia.